<DOC>
	<DOCNO>NCT03067129</DOCNO>
	<brief_summary>An open-label study ass pharmacokinetics ( PK ) , safety , efficacy glecaprevir ( GLE ) /pibrentasvir ( PIB ) pediatric participant divide 4 age group : 3 &lt; 6 , 6 &lt; 9 , 9 &lt; 12 , 12 &lt; 18 year age . Within age group , participant enrol intensive pharmacokinetics ( IPK ) characterize PK particular age group remainder participant enrol evaluation safety efficacy age group . Intensive PK sampling design allow dose adjustment , base available PK clinical data achieve therapeutic exposure safe efficacious adult . Part 1 study enroll participant Cohort 1 ; Cohort 1 include participant 12 &lt; 18 year age swallow adult formulation GLE/PIB . Part 2 study enroll participant remain age group Cohorts 2 , 3 , 4 ; participant cohorts receive pediatric formulation GLE/PIB . All participant receive GLE/PIB 8 , 12 , 16 week depend hepatitis C virus ( HCV ) genotype , cirrhosis , prior treatment experience status .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety , Efficacy Glecaprevir/Pibrentasvir Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Hepatitis C virus ( HCV ) infection demonstrate positive antiHCV antibody ( Ab ) HCV Ribonucleic acid ( RNA ) great equal 1000 IU/ mL . Subject must weight consistent recommend weight range age time screen . Females pregnant breastfeeding . Positive test result Hepatitis B surface antigen ( HbsAg ) positive test result HBV DNA . Participants know liver disease . Decompensated cirrhosis define : presence ascites , history variceal bleeding , lab value consistent Child 's class B C cirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Compensated ( Child-Pugh A ) cirrhosis</keyword>
	<keyword>Treatment na√Øve</keyword>
	<keyword>pegylated interferon ( pegIFN )</keyword>
	<keyword>Ribavirin ( RBV )</keyword>
	<keyword>Chronic Hepatitis C Virus</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Interferon ( IFN )</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Non-cirrhotic cirrhosis</keyword>
	<keyword>Glecaprevir</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>Pibrentasvir</keyword>
</DOC>